CoChat

The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116

Dabkeviciene, Daiva, Jonusiene, Violeta, Zitkute, Vilmante, Zalyte, Egle, Grigaitis, Pranas, Kirveliene, Vida, Sasnauskiene, Ausra · 2015 · Medical Oncology
Cited by 55

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12032-015-0703-y

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 23

  1. Garborg K. Colorectal cancer screening. Surg Clin North Am. 2015;95(5):979–89. · DOI
  2. Gallagher DJ, Kemeny N. Metastatic colorectal cancer: from improved survival to potential cure. Oncology. 2010;78(3–4):237–48. · DOI · Paper page
  3. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–26. · DOI · Paper page
  4. Temraz S, Mukherji D, Alameddine R, Shamseddine A. Methods of overcoming treatment resistance in colorectal cancer. Crit Rev Oncol Hematol. 2014;89(2):217–30. · DOI
  5. Weng W, Feng J, Qin H, Ma Y. Molecular therapy of colorectal cancer: progress and future directions. Int J Cancer. 2015;136(3):493–502. · DOI
  6. Jin WJ, Xu JM, Xu WL, Gu DH, Li PW. Diagnostic value of interleukin-8 in colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol. 2014;20(43):16334–42. · DOI
  7. Ning Y, Lenz HJ. Targeting IL-8 in colorectal cancer. Expert Opin Ther Targets. 2012;16(5):491–7. · DOI
  8. Hwang WL, Yang MH, Tsai ML, Lan HY, Su SH, Chang SC, et al. SNAIL regulates interleukin-8 expression, stem cell-like activity, and tumorigenicity of human colorectal carcinoma cells. Gastroenterology. 2011;141(1):279–91. · DOI · Paper page
  9. Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, et al. Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer. 2011;128(9):2038–49. · DOI · Paper page
  10. Lopetuso LR, Chowdhry S, Pizarro TT. Opposing functions of classic and novel IL-1 family members in gut health and disease. Front Immunol. 2013;4:181. · DOI · Paper page
  11. Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis. 2015;2015(2):196–209. · DOI · Paper page
  12. Angst E, Reber HA, Hines OJ, Eibl G. Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery. 2008;144(1):57–65. · DOI
  13. Dabkeviciene D, Sasnauskiene A, Leman E, Kvietkauskaite R, Kirveliene V. Differential expression of VEGF and IL-1 alpha after photodynamic treatment in combination with doxorubicin or taxotere. Anticancer Res. 2014;34(10):5295–302.
  14. Dabkeviciene D, Sasnauskiene A, Leman E, Kvietkauskaite R, Daugelaviciene N, Stankevicius V, et al. mTHPC-mediated photodynamic treatment up-regulates the cytokines VEGF and IL-1alpha. Photochem Photobiol. 2012;88(2):432–9. · DOI
  15. Hernandez-Alcoceba R, Sangro B, Berraondo P, Gonzalez-Aseguinolaza G, Prieto J. Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. Expert Opin Investig Drugs. 2013;22(7):827–41. · DOI
  16. Verbeke H, Struyf S, Laureys G, Van Damme J. The expression and role of CXC chemokines in colorectal cancer. Cytokine Growth Factor Rev. 2011;22(5–6):345–58. · DOI
  17. van der Mijn JC, Mier JW, Broxterman HJ, Verheul HM. Predictive biomarkers in renal cell cancer: insights in drug resistance mechanisms. Drug Resist Updat. 2014;17(4–6):77–88. · DOI
  18. Liu ZH, Wang MH, Ren HJ, Qu W, Sun LM, Zhang QF, et al. Interleukin 7 signaling prevents apoptosis by regulating bcl-2 and bax via the p53 pathway in human non-small cell lung cancer cells. Int J Clin Exp Pathol. 2014;7(3):870–81.
  19. Lien GS, Wu MS, Bien MY, Chen CH, Lin CH, Chen BC. Epidermal growth factor stimulates nuclear factor-kappaB activation and heme oxygenase-1 expression via c-Src, NADPH oxidase, PI3 K, and Akt in human colon cancer cells. PLoS ONE. 2014;9(8):e104891. · DOI · Paper page
  20. Chen HJ, Edwards R, Tucci S, Bu P, Milsom J, Lee S, et al. Chemokine 25-induced signaling suppresses colon cancer invasion and metastasis. J Clin Invest. 2012;122(9):3184–96. · DOI
  21. Du C, Yao Y, Xue W, Zhu WG, Peng Y, Gu J. The expression of chemokine receptors CXCR3 and CXCR4 in predicting postoperative tumour progression in stages I-II colon cancer: a retrospective study. BMJ Open. 2014;4(8):e005012. · doi:10.1136/bmjopen-2014-005012
  22. Dinarello CA. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 1998;16(5–6):457–99. · DOI · Paper page
  23. Kogan-Sakin I, Cohen M, Paland N, Madar S, Solomon H, Molchadsky A, et al. Prostate stromal cells produce CXCL-1, CXCL-2, CXCL-3 and IL-8 in response to epithelia-secreted IL-1. Carcinogenesis. 2009;30(4):698–705. · DOI

Cited by

See all 55

Metadata

Authors
Dabkeviciene, D., Jonusiene, V., Zitkute, V., Zalyte, E., Grigaitis, P., Kirveliene, V., & Sasnauskiene, A.
Venue
Medical Oncology
Published
2015-10-30
Volume
32
Issue
12
ISSN
  • 1357-0560
  • 1559-131X
Cited by
55
References
4
Language
en
Licence
www.springer.com/tdm (tdm)
Funders
Lietuvos Mokslo Taryba (LT) (MIP-029/2014)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. https://app.cochat.ai/papers/10.1007/s12032-015-0703-y
The paper
Dabkeviciene, D., Jonusiene, V., Zitkute, V., Zalyte, E., Grigaitis, P., Kirveliene, V., & Sasnauskiene, A. (2015). The role of interleukin-8 (CXCL8) and CXCR2 in acquired chemoresistance of human colorectal carcinoma cells HCT116. Medical Oncology. https://doi.org/10.1007/s12032-015-0703-y

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.